Pfizer announced Friday that it is discontinuing development of its twice-daily weight loss pill danuglipron after ... recent study involving adults with obesity and without type 2 diabetes ...

There’s no question, however, that the decision to abandon the twice-daily version introduces a significant delay to Pfizer’s plans to enter the obesity market, which has been transformed in ...

Pfizer said it would stop developing the twice-daily version ... weight loss pill to help it rebound from plummeting demand ...

Pfizer is advancing on a broad front in its attempt to catch up with Novo Nordisk and Eli Lilly in the obesity drug category ... it had decided to drop the twice-daily version, after seeing ...

The transition hasn’t been easy. Company shares dropped again in December when Pfizer said it would abandon its twice-a-day formulation of an obesity pill due to an unacceptably high rate of ...

The market for obesity treatment is expected to expand more than fifteenfold by 2030 due to escalating competition, fueled by ...

That's a surprising finding: Pfizer does not have a single anti-obesity medicine on the ... Pfizer is investigating danuglipron as a twice-daily and once-daily pill, as some patients will prefer ...